Absence of QTc Prolongation with Sodium N-(8-[2-Hydroxybenzoyl] Amino) Caprylate (SNAC), an Absorption Enhancer Co-Formulated with the GLP-1 Analogue Semaglutide for Oral Administration

ConclusionThis QT/QTc trial demonstrates that SNAC doses 12-fold higher than the 300  mg dose used in the oral formulation of semaglutide do not cause unacceptable prolongation of the QTcF interval.Trial RegistrationClinicaltrials.gov identifier: NCT02911870.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research